230 related articles for article (PubMed ID: 11524770)
61. [Effect of retinoic acid on the cytogenetic remission in the first chronic phase of chronic myeloid leukemia treated with interferon].
Egyed M; Mihályfalvi Z; Kollár B; Rumi G; Keller E; Vass J; Fekete S
Orv Hetil; 2001 Nov; 142(44):2421-5. PubMed ID: 11766235
[TBL] [Abstract][Full Text] [Related]
62. Hematopoietic stem cell transplantation in hematologic malignancy.
Archuleta TD; Devetten MP; Armitage JO
Panminerva Med; 2004 Mar; 46(1):61-74. PubMed ID: 15238882
[TBL] [Abstract][Full Text] [Related]
63. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
[TBL] [Abstract][Full Text] [Related]
64. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M
Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141
[TBL] [Abstract][Full Text] [Related]
65. [The effectiveness of interferon-alpha therapy in Ph-positive chronic myeloid leukemia].
Bogdanov KV; Frolova OI; Marinets OV; Ogorodnikova IuS; Afanas'ev BV; Zaritskiĭ AIu
Vopr Onkol; 2003; 49(2):189-92. PubMed ID: 12785203
[TBL] [Abstract][Full Text] [Related]
66. [Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].
Ajima A; Takayama N; Hasegawa Y; Kojima H; Nagasawa T
Gan To Kagaku Ryoho; 2003 Nov; 30(12):1997-9. PubMed ID: 14650975
[TBL] [Abstract][Full Text] [Related]
67. Granulocyte dysfunction in hematological disorders.
Matzner Y
Cancer Invest; 1992; 10(2):155-61. PubMed ID: 1551025
[No Abstract] [Full Text] [Related]
68. [Administration of corticosteroids in hematologic diseases].
Haanen C
Ned Tijdschr Geneeskd; 1978 May; 122(19):671-8. PubMed ID: 652084
[No Abstract] [Full Text] [Related]
69. [Chronic myeloid leukemia].
Udvardy M
Orv Hetil; 2005 Feb; 146(6):243-7. PubMed ID: 15779811
[TBL] [Abstract][Full Text] [Related]
70. [New molecular markers within the chronic myeloproliferative disorders. I: the PRV-1 gene].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3295-9. PubMed ID: 17032591
[TBL] [Abstract][Full Text] [Related]
71. Imatinib results in better quality of life for CML patients than interferon/Ara-C.
J Support Oncol; 2003; 1(1):77. PubMed ID: 15352651
[No Abstract] [Full Text] [Related]
72. Autotransplantation for chronic myeloid leukemia: is it useful?
Olavarria E
Haematologica; 2002 Jan; 87(1):3-6. PubMed ID: 11801458
[No Abstract] [Full Text] [Related]
73. [Chronic neutrophilic leukemia: a long-term analysis of seven cases and review of the literature].
Telek B; Batár P; Udvardy M; László R
Orv Hetil; 2006 May; 147(18):827-30. PubMed ID: 16784137
[TBL] [Abstract][Full Text] [Related]
74. [Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
Liu XL; Zhou SY; Du QF; Zheng WY; Zhang S; Song LL; Xu B; Liu QF; Meng FY
Ai Zheng; 2004 Apr; 23(4):421-5. PubMed ID: 15087031
[TBL] [Abstract][Full Text] [Related]
75. [Review of relationship between tumor necrosis factor genetic polymorphism and hematological malignancies].
Zhao HY; Chen YX
Ai Zheng; 2003 Feb; 22(2):216-20. PubMed ID: 12600304
[TBL] [Abstract][Full Text] [Related]
76. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
77. Cytotoxic effect of interferon on primary malignant tumour cells. Studies in various malignancies.
Grandér D; Xu B; Einhorn S
Eur J Cancer; 1993; 29A(14):1940-3. PubMed ID: 7506559
[TBL] [Abstract][Full Text] [Related]
78. Coexistence of multiple myeloma and chronic myelogenous leukemia.
Tanaka M; Tanaka K; Oizumi K
Int J Hematol; 1999 Aug; 70(2):132-3. PubMed ID: 10497853
[No Abstract] [Full Text] [Related]
79. [Therapy of hematologic diseases using androgens].
Sánchez-Medal L
Munch Med Wochenschr; 1971 Jun; 113(25):960-5. PubMed ID: 5108720
[No Abstract] [Full Text] [Related]
80. [Interferons: Clinical applications in hematology].
Ben Rhomdhane N; Ben Ahmed M; Zitouni M; Mtimet B
Tunis Med; 1998 Dec; 76(12):427-36. PubMed ID: 10093482
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
